Skip to Content
Merck
CN
All Photos(3)

Documents

ABF133

Sigma-Aldrich

Anti-PD-L1 Antibody/CD274

1 mg/mL, from rabbit

Synonym(s):

Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human

species reactivity (predicted by homology)

rhesus macaque (based on 100% sequence homology)

concentration

1 mg/mL

technique(s)

flow cytometry: suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... CD274(29126)

Related Categories

General description

Programmed cell death 1 ligand 1 (PD-L1/CD274) is a B7 related protein belonging to the BTN/MOG family. PDL-1/CD274 is essential for T-cell proliferation and production of IL10 and IFNG. PD-L1/CD274 reduces the secretion of IL-2 and IL-10 from memory T cells by inhibiting cell-mediated immune responses. PD-L1/CD274 may be involved in reducing allogenic CD4+ memory T-cell responses to endothelial cells. PD-L1/CD274 is highly expressed in heart, skeletal muscle, placenta, and lung and weakly expressed in thymus, spleen, kidney, and liver.

Specificity

This antibody should recognize isoforms 1 and 2 based upon immunogen design.

Immunogen

Epitope: This antibody recognizes the Ig-like C2-type domain in the extracellular domain of PD-L1/CD274.
KLH-conjugated linear peptide corresponding to the extracellular domain of human PD-L1/CD274.

Application

Anti-PD-L1 Antibody/CD274 is an antibody against PD-L1/CD274 for use in western blotting & flow cytometry.
Research Category
Inflammation & Immunology
Research Sub Category
Immunological Signaling
Western Blotting Analysis: 2 µg/mL from a representative lot detected PD-L1/CD274 in 10 µg of K562 cell lysate.

Flow Cytometry Analysis: 0.25 µg from a representative lot detected PD-L1/CD274 in 1X10E6 K562 cells.

Quality

Evaluated by Western Blotting in Jurkat cell lysate.

Western Blotting Analysis: 2 µg/mL of this antibody detected PD-L1/CD274 in 10 µg of Jurkat cell lysate.

Target description

~55 kDa and ~33 kDa observed. Uniprot describes three isoforms at 33 kDa, 20 kDa and 21 kDa This antibody contains 4 known glyscosylation sytes. An unglycosylated and glycosylated/membrane form may be observed at 34 kDa and 55 kDa, respectively.

Physical form

Affinity purified
Purified rabbit Polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Caterina Costa et al.
Cell death & disease, 11(9), 748-748 (2020-09-16)
Malignant pleural mesothelioma (MPM) is an aggressive cancer, related to asbestos exposure, which has a dismal prognosis. MPM diagnosis is late and often challenging, suggesting the need to identify more reliable molecular biomarkers. Here, we set out to identify differentially
Aurélien Marabelle et al.
Oncoimmunology, 5(3), e1068494-e1068494 (2016-05-04)
Cancer immunotherapy has been one of the dominant topics in oral presentations and abstracts during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The renewed interest in immunotherapy is explained by the wide spectrum of activity
Maximilian J Mair et al.
ESMO open, 5(6), e000863-e000863 (2020-11-14)
Immune-modulatory treatments have so far shown limited clinical activity in primary brain tumours. We aimed to investigate soluble programmed death receptor ligand 1 (sPD-L1) as systemic inflammation parameter in patients with brain tumour. EDTA plasma was collected from 81 glioma
Hui Gong et al.
Cellular and molecular life sciences : CMLS, 81(1), 39-39 (2024-01-12)
Colorectal cancer (CRC) is characterized by a complex tumor inflammatory microenvironment, while angiogenesis and immunosuppression frequently occur concomitantly. However, the exact mechanism that controls angiogenesis and immunosuppression in CRC microenvironment remains unclear. Herein, we found that expression levels of lipid

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service